FDA approval of Amivantamab-Vmjw in combination with carboplatin and pemetrexed for EGFR-mutated NSCLC: a new therapeutic milestone.

Ann Med Surg (Lond) · 2025 · PMC11981408 · PMID 40213223

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Although the OS data at the second interim analysis did not show a statistically significant difference, the hazard ratio of 0.73 suggested a positive trend that warrants further investigation.

also in 6,846 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.